Oncology

News

Hernexeos box, two pills, and pill bottle

Boehringer gets FDA's second 'national priority' approval

Boehringer Ingelheim's lung cancer drug Hernexeos has become the second medicine approved after an FDA national priority review.

News

Generate's IPO gets over the line, raising $400m

AI-powered drug developer Generate Biomedicine completes a $400m IPO, the largest for biotech on the Nasdaq so far this year.

News

MSD splits pharma business, hiving off oncology

MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.

News

FDA clears first all-oral combo for first-line CLL treatment

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

News

Gilead buys cell therapy partner Arcellx for up to $7.8bn

Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.

News

Elderly man talks to younger female nurse beside a Grail screening vehicle

Grail's multi-cancer test fluffs its lines in UK trial

Grail's Galleri blood test for cancer screening missed the mark in the much-anticipated NHS-Galleri trial, wreaking havoc with the firm's share price.

Boehringer gets FDA's second 'national priority' approval

Generate's IPO gets over the line, raising $400m

MSD splits pharma business, hiving off oncology

FDA clears first all-oral combo for first-line CLL treatment

Gilead buys cell therapy partner Arcellx for up to $7.8bn

Grail's multi-cancer test fluffs its lines in UK trial

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

Oncology

Editor's Picks